P‐glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)‐[ 11 C]verapamil PET-Reference-Cited by-同舟云学术

P‐glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)‐[ 11 C]verapamil PET

Published:2020-07 Issue:7 Volume:61 Page:1472-1480
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Ilyas‐Feldmann Maria¹²³⁴^ORCID,Asselin Marie‐Claude³,Wang Shaonan³⁵,McMahon Adam³,Anton‐Rodriguez José³,Brown Gavin³,Hinz Rainer³^ORCID,Duncan John S.¹²^ORCID,Sisodiya Sanjay M.¹²^ORCID,Koepp Matthias¹²

Affiliation:

1. Department of Clinical and Experimental Epilepsy University College London Queen Square Institute of Neurology London UK

2. Chalfont Centre for Epilepsy Bucks UK

3. Wolfson Molecular Imaging Centre University of Manchester Manchester UK

4. Department of Neurology Epilepsy‐Center Berlin‐Brandenburg Charité ‐ Universitätsmedizin Berlin Berlin Germany

5. Global Pharmacometrics Boehringer Ingelheim Ingelheim am Rhein Germany

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.16581

Reference26 articles.

1. Early Identification of Refractory Epilepsy

2. MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy

3. Neuropathology of the blood–brain barrier and pharmaco-resistance in human epilepsy

4. Region-Specific Overexpression of P-glycoprotein at the Blood-Brain Barrier Affects Brain Uptake of Phenytoin in Epileptic Rats

5. Widespread Upregulation of Drug‐resistance Proteins in Fatal Human Status Epilepticus

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, Preclinical Toxicity, and Biodistribution of [¹⁸F]AVT-011 to Assess the P-Glycoprotein Function;Cancer Biotherapy and Radiopharmaceuticals;2024-09-12

2. Tolerability of tariquidar – A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsy;Seizure: European Journal of Epilepsy;2024-07

3. Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions;Expert Opinion on Drug Delivery;2024-05-03

4. Pathophysiology of drug-resistant canine epilepsy;The Veterinary Journal;2023-06

5. Targeting adverse effects of antiseizure medication on offspring: current evidence and new strategies for safety;Expert Review of Neurotherapeutics;2023-02-01